| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Virology, Faculty of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK
2 Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0440, USA
3 EBV Biology Laboratory, Division of Immunology and Infectious Diseases, Queensland Institute of Medical Research, Herston, QLD 4006, Australia
Correspondence
Geoffrey L. Smith
glsmith{at}imperial.ac.uk
Vaccinia virus (VACV) is the vaccine that was used to eradicate smallpox and is being developed as a recombinant vaccine for other pathogens. Removal of genes encoding immunomodulatory proteins expressed by VACV may enhance virus immunogenicity and improve its potential as a vaccine. Protein A41 is a candidate for removal, having sequence similarity to the VACV chemokine-binding protein, vCKBP, and an association with reduced inflammation during dermal infection. Here, it is shown that, at low doses, VACV strain Western Reserve (WR) lacking A41L (v
A41L) was slightly more virulent than wild-type and revertant controls after intranasal infection of BALB/c mice. The primary immune response to vA41L was marked by an increase in the percentage of VACV-specific gamma interferon-producing CD8+ T cells and enhancement of cytotoxic T-cell responses in the spleen. However, this augmentation of cellular response was not seen in lung infiltrates. Splenic CD8+ T-cell responses were also enhanced when VACV strain modified vaccinia virus Ankara (MVA) lacking A41L was used to immunize mice. Lastly, immunization with VACV MVA lacking A41L provided better protection than control viruses to subsequent challenge with a 300 LD50 dose of VACV WR. This study provides insight into the immunomodulatory role of A41 and suggests that MVA lacking A41 may represent a more efficacious vaccine.
These authors contributed equally to this work.
This article has been cited by other articles:
|
|
 |
|
  N. Jacobs, N. W. Bartlett, R. H. Clark, and G. L. Smith Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection J. Gen. Virol., November 1, 2008; 89(11): 2877 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Fahy, R. H. Clark, E. F. Glyde, and G. L. Smith Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence J. Gen. Virol., October 1, 2008; 89(10): 2377 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Ruiz-Arguello, V. P. Smith, G. S. V. Campanella, F. Baleux, F. Arenzana-Seisdedos, A. D. Luster, and A. Alcami An Ectromelia Virus Protein That Interacts with Chemokines through Their Glycosaminoglycan Binding Domain J. Virol., January 15, 2008; 82(2): 917 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Fischer, D. C. Tscharke, K. B. Donohue, M. E. Truckenmiller, and C. C. Norbury Reduction of vector gene expression increases foreign antigen-specific CD8+ T-cell priming J. Gen. Virol., September 1, 2007; 88(9): 2378 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gubser, R. Goodbody, A. Ecker, G. Brady, L. A. J. O'Neill, N. Jacobs, and G. L. Smith Camelpox virus encodes a schlafen-like protein that affects orthopoxvirus virulence J. Gen. Virol., June 1, 2007; 88(6): 1667 - 1676. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
